Paradigm $3.10Equities research analysts at Paradigm Capital increased their target price on shares of ProMetic Life Sciences (TSE:PLI) from C$2.90 to C$3.10 in a research note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Paradigm Capital’s price target suggests a potential upside of 59.79% from the company’s current price https://sleekmoney.com/prometic-life-sciences-price-target-raised-to-c3-10-at-paradigm-capital-pli/71627/